ClinicalTrials.gg
CompletedNCT04818346Updated Apr 11, 2024Results posted

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

A Phase 2 interventional study of INCB054707 and Placebo in NonSegmental Vitiligo, sponsored by Incyte Corporation. Completed at 31 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-11.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
171
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Vitiligo by Incyte Corporation — 2 open to participants now, 4 under way, 4 of them phase 3. Vitiligo · Incyte Corporation.

Enrollment
8th of 12
171 · median 215
Started
2021
with 1 other
Phase 2
5 of 12
none open now
Registered
5th of 12
by date

Among the 12 studies in Vitiligo by Incyte Corporation, this one is the 8th largest by enrollment, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 5th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

2 of the 12 studies in Vitiligo by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Vitiligo by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of INCB054707 over a 24-week placebo-controlled double-blind treatment period, followed by a 28-week double-blind extension period in participants with nonsegmental vitiligo.

03

Conditions studied

  • NonSegmental Vitiligo

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of nonsegmental vitiligo.
  • History of prior vitiligo treatment with a total duration of at least 3 months.
  • Agreement to discontinue all agents and procedures used to treat vitiligo from screening through the final safety follow-up visit.
  • Willingness to avoid pregnancy or fathering children
  • Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Other forms of vitiligo (eg, segmental) or other skin depigmentation disorders.
  • Uncontrolled thyroid function at screening as determined by the investigator.
  • Women who are pregnant (or who are considering pregnancy) or lactating.
  • Medical history including thrombocytopenia, coagulopathy or dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator.
  • Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis.
  • Participants known to be infected with , , or .
  • Laboratory values outside of the protocol-defined ranges.
  • Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    INCB054707 Dose A followed by Dose C

    Participants will receive INCB054707 Dose A for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).

    Drug: INCB054707

  • Experimental
    INCB054707 Dose B

    Participants will receive INCB054707 Dose B for 52 weeks (Period 1 + Period 2).

    Drug: INCB054707

  • Experimental
    INCB054707 Dose C

    Participants will receive INCB054707 Dose C for 52 weeks (Period 1 + Period 2).

    Drug: INCB054707

  • Placebo comparator
    Placebo followed by INCB054707 Dose C

    Participants will receive placebo for 24 weeks (Period 1) followed by INCB054707 Dose C for 28 weeks (Period 2).

    Drug: Placebo

Interventions

  • INCB054707 will be administered once daily

    Also known as: Povorcitinib

  • DrugPlacebo

    Placebo or INCB054707 will be administered once daily

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24

    The T-VASI was calculated based on values from the whole body, which was split into 6 separate and mutually exclusive regions (possible range: 0-100; higher values=worse outcome). The percentage of vitiligo involvement was estimated in hand units (% body surface area \[BSA\]; investigator assessed), based on the participant's hand size. The degree of depigmentation for each body site was determined and estimated to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The T-VASI was derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values of all body sites. Percent change was calculated as (\[post-Baseline value minus the Baseline value\] / Baseline value) x 100.

    Time frame: Baseline; Week 24

Secondary outcomes

  1. Percentage of Participants Achieving T-VASI50 at Week 24

    T-VASI50 was defined as a 50% or greater reduction from Baseline in T-VASI. The T-VASI was calculated based on values from the whole body, which was split into 6 separate and mutually exclusive body regions (possible range: 0-100; higher values=worse outcome). The percentage of vitiligo involvement was estimated in hand units (% body surface area \[BSA\]; investigator assessed), based on the participant's hand size. The degree of depigmentation for each body site was determined and estimated to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The T-VASI was derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values of all body sites.

    Time frame: Baseline; Week 24

  2. Placebo-controlled Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up period.

    Time frame: up to Week 24

  3. Extension Period: Number of Participants With Any TEAE

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up period.

    Time frame: from Week 25 up to Week 76

07

Results

Posted Jul 5, 2023

Participant flow

24-Week Placebo-controlled Period
Participant flow — 24-Week Placebo-controlled Period
MilestonePlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mg
Started43434342
Completed35383234
Not completed85118
Withdrew: Adverse event1203
Withdrew: Lost to follow-up3231
Withdrew: Physician decision1000
Withdrew: Protocol violation0011
Withdrew: Withdrawal by subject1162
Withdrew: Subject terminated by sponsor1000
Withdrew: Latent tuberculosis; unable to provide proof of treatment1000
Withdrew: Use of prohibited concomitant medication0010
Withdrew: Ineligible to be included in the study due to abnormal coagulation profile0001
28-Week Double-blind Extension Period
Participant flow — 28-Week Double-blind Extension Period
MilestonePlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mg
Started35373234
Completed33302628
Not completed2766
Withdrew: Adverse event1011
Withdrew: Lost to follow-up1211
Withdrew: Withdrawal by subject0343
Withdrew: Non-compliance0100
Withdrew: Non-compliance with study drug0100
Withdrew: Scheduling conflicts0001

Outcome measures

PrimaryPercent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24

The T-VASI was calculated based on values from the whole body, which was split into 6 separate and mutually exclusive regions (possible range: 0-100; higher values=worse outcome). The percentage of vitiligo involvement was estimated in hand units (% body surface area \[BSA\]; investigator assessed), based on the participant's hand size. The degree of depigmentation for each body site was determined and estimated to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The T-VASI was derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values of all body sites. Percent change was calculated as (\[post-Baseline value minus the Baseline value\] / Baseline value) x 100.

Time frame:
Baseline; Week 24
Reported as:
Geometric least squares mean · percent change
Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 24
percent changePlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mg
Percent Change From Baseline in Total Vitiligo Area Scoring Index (T-VASI) at Week 242.29 ± 4.81-19.12 ± 4.56-17.78 ± 4.87-15.73 ± 4.74
Statistical analysis
  • Placebo vs Povorcitinib 15 mg · Mixed Model Repeated Measures (MMRM) · p = 0.0015 · Least squares mean difference: -21.41 · 95% CI -34.49 to -8.32
  • Placebo vs Povorcitinib 45 mg · MMRM · p = 0.0040 · Least squares mean difference: -20.07 · 95% CI -33.63 to -6.51
  • Placebo vs Povorcitinib 75 mg · MMRM · p = 0.0086 · Least squares mean difference: -18.02 · 95% CI -31.40 to -4.64
SecondaryPercentage of Participants Achieving T-VASI50 at Week 24

T-VASI50 was defined as a 50% or greater reduction from Baseline in T-VASI. The T-VASI was calculated based on values from the whole body, which was split into 6 separate and mutually exclusive body regions (possible range: 0-100; higher values=worse outcome). The percentage of vitiligo involvement was estimated in hand units (% body surface area \[BSA\]; investigator assessed), based on the participant's hand size. The degree of depigmentation for each body site was determined and estimated to the nearest percentage: 0%, 10%, 25%, 50%, 75%, 90%, or 100%. The T-VASI was derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each body site and summing the values of all body sites.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving T-VASI50 at Week 24
percentage of participantsPlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mg
Percentage of Participants Achieving T-VASI50 at Week 242.3 (0.1 to 12.3)9.3 (2.6 to 22.1)11.6 (3.9 to 25.1)4.8 (0.6 to 16.2)
Statistical analysis
  • Placebo vs Povorcitinib 15 mg · Wald test · p = 0.3574 · Odds ratio (or): 4.3 · 95% CI 0.398 to 220.998Logistic regression: (response at Week 24 = treatment + stratification factor \[T-BSA involvement 8%-20%/\>20%\]).
  • Placebo vs Povorcitinib 45 mg · Wald test · p = 0.1992 · Odds ratio (or): 5.5 · 95% CI 0.573 to 273.479Logistic regression: (response at Week 24 = treatment + stratification factor \[T-BSA involvement 8%-20%/\>20%\]).
  • Placebo vs Povorcitinib 75 mg · Wald test · p = 0.9913 · Odds ratio (or): 2.1 · 95% CI 0.103 to 126.386Logistic regression: (response at Week 24 = treatment + stratification factor \[T-BSA involvement 8%-20%/\>20%\]).
SecondaryPlacebo-controlled Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up period.

Time frame:
up to Week 24
Reported as:
Count of participants · Participants
Placebo-controlled Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsPlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mg
Placebo-controlled Period: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)24293035
SecondaryExtension Period: Number of Participants With Any TEAE

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An AE could therefore have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the study drug. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug until the end of the safety follow-up period.

Time frame:
from Week 25 up to Week 76
Reported as:
Count of participants · Participants
Extension Period: Number of Participants With Any TEAE
ParticipantsPlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mg
Extension Period: Number of Participants With Any TEAE27282131

Adverse events

Collected over up to Week 76. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/42 (0%)1/42 (2.4%)19/42 (45.2%)
Povorcitinib 15 mg0/43 (0%)0/43 (0%)22/43 (51.2%)
Povorcitinib 45 mg0/41 (0%)1/41 (2.4%)24/41 (58.5%)
Povorcitinib 75 mg0/114 (0%)1/114 (0.9%)69/114 (60.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mg
COVID-19Infections and infestations0/420/431/410/114
Acetabulum fractureInjury, poisoning and procedural complications1/420/430/410/114
Pelvic fractureInjury, poisoning and procedural complications1/420/430/410/114
Road traffic accidentInjury, poisoning and procedural complications1/420/430/410/114
Spinal fractureInjury, poisoning and procedural complications1/420/430/410/114
Substance-induced psychotic disorderPsychiatric disorders0/420/430/411/114
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mg
COVID-19Infections and infestations5/428/4313/4131/114
AcneSkin and subcutaneous tissue disorders0/420/433/4122/114
Blood creatine phosphokinase increasedInvestigations3/423/434/4121/114
HeadacheNervous system disorders5/427/431/419/114
Upper respiratory tract infectionInfections and infestations1/423/436/416/114
Aspartate aminotransferase increasedInvestigations1/421/434/414/114
Urinary tract infectionInfections and infestations1/421/434/415/114
NasopharyngitisInfections and infestations3/420/432/419/114
Alanine aminotransferase increasedInvestigations1/421/433/416/114
DiarrhoeaGastrointestinal disorders1/420/433/412/114

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mgTotal
Mean48.6 ± 12.9245.9 ± 11.5650.2 ± 11.6150.5 ± 11.6948.8 ± 11.99
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mgTotal
Female2429211993
Male1914222378
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mgTotal
White/Caucasian34323828132
Black/African-American23139
Asian240713
Mexican American10001
African-European10001
Middle Eastern01102
Columbian00011
Captured as Hispanic in Database00022
Mixed01001
Mexican00101
East Indian10001
Did Not Identify with Options Provided01001
White and Asian-Non-Japanese00101
South African01001
White/Black10001
South American00011
Egyptian00101
Captured as Hispanic/Latino in Database10001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mgTotal
Hispanic or Latino8611732
Not Hispanic or Latino35363234137
Not Reported00011
Bangladeshi01001
Total Vitiligo Area Scoring Index (T-VASI)
Total Vitiligo Area Scoring Index (T-VASI)(scores on a scale)PlaceboPovorcitinib 15 mgPovorcitinib 45 mgPovorcitinib 75 mgTotal
Mean28.31 ± 21.48127.13 ± 20.08523.64 ± 19.75822.65 ± 14.24425.45 ± 19.094
08

Study locations

31 sites
  • Investigative Site 010
    Hoover, Alabama 35244, United States
  • Investigative Site 015
    Gilbert, Arizona 85295, United States
  • Investigative Site 028
    Scottsdale, Arizona 85260, United States
  • Investigative Site 006
    Irvine, California 92697, United States
  • Investigative Site 009
    Los Angeles, California 90036, United States
  • Investigative Site 018
    Los Angeles, California 90045, United States
  • Investigative Site 017
    Sacramento, California 95815, United States
  • Investigative Site 032
    Orange Park, Florida 32073, United States
  • Investigative Site 005
    Tampa, Florida 33613, United States
  • Investigative Site 022
    Tampa, Florida 33614, United States
  • Investigative Site 011
    West Palm Beach, Florida 33401, United States
  • Investigative Site 024
    Covington, Louisiana 70433, United States
  • Investigative Site 002
    Brighton, Massachusetts 02135, United States
  • Investigative Site 023
    Saint Paul, Minnesota 55112, United States
  • Investigative Site 027
    Verona, New Jersey 07044, United States
  • Investigative Site 003
    Columbus, Ohio 43215, United States
  • Investigative Site 007
    Norman, Oklahoma 73071, United States
  • Investigative Site 001
    Portland, Oregon 97223, United States
  • Investigative Site 021
    Plymouth Meeting, Pennsylvania 19462, United States
  • Investigative Site 004
    Murfreesboro, Tennessee 37130, United States
  • Investigative Site 033
    Dallas, Texas 75230, United States
  • Investigative Site 012
    San Antonio, Texas 78213, United States
  • Investigative Site 030
    Spokane, Washington 99202, United States
  • Investigative Site 020
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Investigative Site 014
    Etobicoke, Ontario M8X 1Y9, Canada
  • Investigative Site 034
    London, Ontario N6H 5LR, Canada
  • Investigative Site 025
    Mississauga, Ontario L5H 1G9, Canada
  • Investigative Site 026
    North York, Ontario M2M4J5, Canada
  • Investigative Site 031
    Oakville, Ontario L6J 7W5, Canada
  • Investigative Site 008
    Peterborough, Ontario K9J 5K2, Canada
  • Investigative Site 029
    Quebec, Q1V 4X7, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in May 2022, 12 months.

Results were first posted in Jul 2023, 1 year 1 month after primary completion.

Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2021
First posted
Mar 26, 2021
StartActual
May 6, 2021
Primary completionActual
May 24, 2022
CompletionActual
May 24, 2023
Results first posted
Jul 5, 2023
Last update
Apr 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04818346
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Mar 26, 2021
Start date
May 6, 2021
Primary completion
May 24, 2022
Completion
May 24, 2023
Results posted
Jul 5, 2023
Last update
Apr 11, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povorcitinib

Start the discussion